Capricor Therapeutics (CAPR) Profit After Tax (2010 - 2026)

Capricor Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$34.5 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 46.19% year-over-year to -$34.5 million; the TTM figure through Mar 2026 stood at -$116.4 million (down 118.29% YoY), while the FY2025 annual figure was -$105.8 million, down 166.63% from the prior year.
• Profit After Tax for Q1 2026 stood at -$34.5 million, down from -$30.9 million in the prior quarter.
• The five-year high for Profit After Tax was -$770053.0 in Q4 2023, with the low at -$34.5 million in Q1 2026.
• The 5-year median for Profit After Tax is -$7.8 million (2022), against an average of -$13.6 million.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax soared 90.02% in 2023, then plunged 703.3% in 2024.
• Capricor Therapeutics' Profit After Tax stood at -$7.7 million in 2022, then surged by 90.02% to -$770053.0 in 2023, then sank by 703.3% to -$6.2 million in 2024, then tumbled by 399.76% to -$30.9 million in 2025, then slipped by 11.6% to -$34.5 million in 2026.
• Business Quant data shows CAPR's Profit After Tax at -$34.5 million in Q1 2026, -$30.9 million in Q4 2025, and -$25.1 million in Q3 2025.